STOCK TITAN

Societal CDMO to Report Financial Results for Third Quarter 2023 on November 8, 2023

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Rhea-AI Summary
Societal CDMO, Inc. will release its financial results for the third quarter of 2023 on November 8, 2023, after the market close. The management team will host a webcast at 4:30 p.m. ET on the same day to discuss the financial results and recent operational highlights. The webcast can be accessed on the company's website and will be available for 30 days.
Positive
  • None.
Negative
  • None.

Webcast Scheduled for Wednesday, November 8, 2023, at 4:30 p.m. Eastern

SAN DIEGO and GAINESVILLE, Ga., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (“Societal CDMO” or “Societal”; NASD: SCTL), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced that the company will release financial results for the third quarter 2023 after the market close on Wednesday, November 8, 2023. Societal’s management team will host a webcast at 4:30 p.m. ET on that day to discuss the financial results and recent operational highlights.

A live webcast can be accessed by visiting the “Investor Events” page in the Investor section of the company’s website: https://ir.societalcdmo.com/events. In addition, an archived webcast will be available on the company’s website approximately two hours after the event and will be available for 30 days.

About Societal CDMO
Societal CDMO (NASDAQ: SCTL) is a bi-coastal contract development and manufacturing organization (CDMO) with capabilities spanning pre-Investigational New Drug (IND) development to commercial manufacturing and packaging for a wide range of therapeutic dosage forms with a primary focus in the area of small molecules. With an expertise in solving complex manufacturing problems, Societal CDMO is a leading CDMO providing therapeutic development, end-to-end regulatory support, clinical and commercial manufacturing, aseptic fill/finish, lyophilization, packaging and logistics services to the global pharmaceutical market.

In addition to our experience in handling DEA controlled substances and developing and manufacturing modified-release dosage forms, Societal CDMO has the expertise to deliver on our clients’ pharmaceutical development and manufacturing projects, regardless of complexity level. We do all of this in our best-in-class facilities, which total 145,000 square feet, in Gainesville, Georgia and San Diego, California.

Societal CDMO: Bringing Science to Society. For more information about Societal CDMO’s customer solutions, visit societalcdmo.com.


Societal CDMO will release its financial results for the third quarter of 2023 on November 8, 2023, after the market close.

The webcast is scheduled for 4:30 p.m. Eastern Time.

The webcast can be accessed on the 'Investor Events' page in the Investor section of Societal CDMO's website.

Yes, an archived webcast will be available on Societal CDMO's website approximately two hours after the event and will be available for 30 days.
Societal CDMO Inc

NASDAQ:SCTL

SCTL Rankings

SCTL Latest News

SCTL Stock Data

Pharmaceutical Preparation Manufacturing
Manufacturing
Link

About SCTL

recro gainesville, llc, provides solid dosage form development, clinical and commercial manufacturing, and packaging and logistics services to the global pharmaceutical market. specializing in extended release solid dose and dea controlled substances, recro has the experts to deliver clients’ most complex pharmaceutical development and manufacturing projects in its best-in-class, 97,000-square-foot manufacturing facility. for more information about recro’s flexible cdmo solutions, visit www.recrogainesville.com